Search research articles
Contact Us
Filters
Showing results (201-210 of 336) with videos related to
Page
of 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Therapeutic Advances in Urology
|
April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
Sebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Clinical Genitourinary Cancer
|
April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)
|
May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Sergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Cancer Medicine
|
March 21, 2022
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study
Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, et al.
Frontiers in Oncology
|
June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Page
of 34
Search research articles
Search
Showing results (201-210 of 336) with videos related to
Sort By:
Page
of 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Therapeutic Advances in Urology
|
April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
Sebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Clinical Genitourinary Cancer
|
April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)
|
May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Sergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Cancer Medicine
|
March 21, 2022
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study
Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, et al.
Frontiers in Oncology
|
June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Page
of 34